Novel findings underscore promise of H3 Biomedicine’s first-in-class splicing factor modulator H3B-8800 currently in Phase 1 clinical trial for patients… Read More
Hotspot mutations in splicing factor genes have been recently reported at high frequency in hematological malignancies, suggesting the importance of… Read More
Gene fusions represent an important class of somatic alterations in cancer. We systematically investigated fusions in 9,624 tumors across 33… Read More
To identify novel targets for acute myeloid leukemia (AML) therapy, we performed genome-wide CRISPR-Cas9 screening using AML cell lines, followed… Read More
H3B-8800 is first known investigational therapy to target RNA splicing factor mutations, highly prevalent in many hematologic cancers Initial data… Read More